Every 10-Q that UnitedHealth Group Incorporated (UNH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UNH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNH filings page.
UnitedHealth Group reported solid second‑quarter 2026 results with total revenues of $112.0 billion, roughly flat year over year, while profitability improved sharply. Net earnings attributable to common shareholders rose to $5.48 billion from $3.41 billion, and diluted EPS increased to $6.04 from $3.74.
For the first six months of 2026, revenues were $223.8 billion, up 1%, with net earnings attributable to shareholders of $11.76 billion, up 21%. Operating performance improved as the medical care ratio declined to 86.7% from 89.4% and the operating margin expanded to 7.1% from 4.6%. Operating cash flow was very strong at $20.0 billion in the first half.
Membership declined, with UnitedHealthcare medical enrollment down to 48.5 million, including 9% reductions in Medicare Advantage and Medicaid lives, reflecting funding pressures, pricing and benefit actions, and state eligibility changes. Optum Health revenues fell 5% on fewer value‑based care patients, though segment earnings increased on cost management and reserve releases. The company raised its annualized dividend to $9.28 per share, repurchased about 10.5 million shares year‑to‑date, reduced long‑term debt, and completed portfolio divestitures while planning a $3.0 billion health care acquisition.
UnitedHealth Group reported Q1 2026 results with modest growth and stable profitability. Total revenues were $111,721 million, up 2% year over year, while net earnings were $6,481 million and diluted EPS was $6.90, roughly in line with 2025.
UnitedHealthcare revenues rose 2% to $86,265 million, but medical membership fell by 1.1 million people, mainly in Medicare Advantage, Medicaid and commercial risk-based products. Optum revenues were flat at $63,749 million and earnings from operations declined 15% as value-based care businesses faced elevated medical cost trends and Medicare funding pressure.
The medical care ratio improved to 83.9% from 84.8% on favorable reserve development and affordability initiatives, while the operating cost ratio increased to 13.8% due to investments and restructuring. Cash flows from operations were strong at $8,912 million. The company executed portfolio divestitures, is exiting South American operations, plans about $3.0 billion of pending acquisitions, entered forward share repurchase contracts up to $2.0 billion, and received IRS Notices of Proposed Adjustment for 2017–2020 transfer pricing, which it intends to contest.
UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.
Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.
Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.
UnitedHealth Group reported second-quarter 2025 consolidated revenue of $111.6 billion, up 13% from $98.9 billion a year earlier, driven by premium growth (+14% to $87.9 billion), Optum Rx volume growth and pricing trends. Despite higher revenue, earnings from operations fell to $5.15 billion (down 35%) and net earnings were $3.57 billion (diluted EPS $3.74), reflecting elevated medical costs and Medicare Advantage funding pressures.
Medical costs rose 20% to $78.6 billion for the quarter, pushing the medical care ratio to 89.4% from 85.1%. Year-to-date results show net earnings of $10.05 billion and diluted EPS of $10.61, strong cash from operations of $12.6 billion for six months, available liquidity of about $77.3 billion in cash and investments, a June dividend increase to an $8.84 annual rate, $3.0 billion of senior notes issued in June, and approximately $4 billion of anticipated acquisition capital committed (subject to approvals).